|
1.
|
|
18 p, 3.7 MB |
The KMT2A recombinome of acute leukemias in 2023
/
Meyer, Claus (DCAL/Institute of Pharm. Biology. Goethe-University(Alemanya)) ;
Larghero, Patrizia (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Lopes, BA. (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Burmeister, Thomas (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany) ;
Gröger, Daniela (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin (Alemanya)) ;
Sutton, Rosemary (Molecular Diagnostics. Children's Cancer Institute. Lowy Cancer Research Centre. UNSW (Sidney, Austràlia)) ;
Venn, Nicola C. (Molecular Diagnostics. Children's Cancer Institute. Lowy Cancer Research Centre. UNSW (Sidney, Austràlia)) ;
Cazzaniga, Giovanni (University of Milano-Bicocca/Fondazione Tettamanti (Itàlia)) ;
Corral Abascal, Lilia (University of Milano-Bicocca/Fondazione Tettamanti (Itàlia)) ;
Tsaur, Grigory А. (Research Institute of Medical Cell Technologies (Ekaterinburg, Rússia)) ;
Fechina, Larisa G. (Research Institute of Medical Cell Technologies (Ekaterinburg, Rússia)) ;
Emerenciano, Mariana (Instituto Nacional de Câncer (INCA)(Rio de Janeiro, Brasil)) ;
Pombo-de-Oliveira, Maria S. (Instituto Nacional de Câncer (INCA)(Rio de Janeiro, Brasil)) ;
Lund-Aho, Tiina (Laboratory of Clinical Genetics, Fimlab Laboratories (Tampere, Finlàndia)) ;
Lundán, Tuija (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Montonen, M. (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Juvonen, Vesa (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Zuna, Jan (Charles University and University Hospital Motol (Praga, República Txeca)) ;
Trka, Jan M. (Charles University and University Hospital Motol (Praga, República Txeca)) ;
Ballerini, Paola (Pierre et Marie Curie University (París, França)) ;
Lapillonne, Hélène (Pierre et Marie Curie University (París, França)) ;
Van der Velden, Vincent (University Medical Center Rotterdam (Països Baixos)) ;
Sonneveld, Edwin (Princess Máxima Center for Pediatric Oncology (Utrecht, Països Baixos)) ;
Delabesse, Éric C. M. (Institut Universitaire du Cancer de Toulouse (França)) ;
Capela de Matos, Roberto (National Cancer Institute (INCA) (Rio de Janeiro, Brasil)) ;
Silva, Maria Luiza (National Cancer Institute (INCA) (Rio de Janeiro, Brasil)) ;
Bomken, Simon (Newcastle University, Newcastle upon Tyne (Regne Unit)) ;
Katsibardi, Katerina (National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital (Atenes, Grècia)) ;
Keernik, Maria (Tartu University Hospital (Tartu, Estònia)) ;
Grardel, Nathalie (University Hospital Claude Huriez) ;
Mason, J. (Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory (Regne Unit)) ;
Price, Richard (Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory (Regne Unit)) ;
Kim, J. (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Eckert, Cornelia (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin (Alemanya)) ;
Lo Nigro, Luca (Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico" (Catània, Itàlia)) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico" (Catània, Itàlia)) ;
Zur Stadt, Udo (University Medical Center Hamburg-Eppendorf (Hamburg, Alemanya)) ;
Gameiro, Paula (Instituto Português de Oncologia, Departament of Hematology (Lisboa, Portugal)) ;
Sedek, Łukasz (Medical University of Silesia (Zabrze, Polònia)) ;
Szczepanski, Tomasz (Medical University of Silesia (Zabrze, Polònia)) ;
Bidet, A. (Laboratoire d'Hématologie Biologique, CHU Bordeaux (França)) ;
Marcu, Victoria (Hematology Laboratory, Sheba Medical Center, Tel-Hashomer, Israel) ;
Shichrur, Keren (Schneider Children's Medical Center of Israel, Petah Tikva, Israel) ;
Izraeli, Shai (Tel Aviv University, Tel Aviv, Israel) ;
Madsen, Hans Ole (Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark) ;
Schäfer, Beat (University Children's Hospital Zurich (Zúric, Suïssa)) ;
Kubetzko, Susanne (University Children's Hospital Zurich (Zúric, Suïssa)) ;
Kim, Rathana (Université Paris Cité (França)) ;
Clappier, Emmanuelle (Université Paris Cité (França)) ;
Trautmann, Heiko (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Brüggemann, Monika (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Archer, Paul (Bristol Genetics Laboratory, North Bristol NHS Trust (Bristol, Regne Unit)) ;
Hancock, Jeremy P. (Bristol Genetics Laboratory, North Bristol NHS Trust (Bristol, Regne Unit)) ;
Alten, Julia (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Möricke, Anja (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Stanulla, Martin (Department of Pediatrics, MHH (Hanover, Alemanya)) ;
Lentes, Jana (Medical School Hannover (Alemanya)) ;
Bergmann, Anke K. (Medical School Hannover (Alemanya)) ;
Strehl, Sabine (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Köhrer, Stefan (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Nebral, Karin (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Dworzak, Michael Norbert (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Haas, Oskar A. (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Arfeuille, Chloe (Hopital Robert Debré (París, França)) ;
Caye Eude, Aurélie (Hopital Robert Debré (París, França)) ;
Cavé, Hélène (Hopital Robert Debré (París, França)) ;
Marschalek, Rolf (Goethe-University (Alemanya))
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. [...]
2023 -  10.1038/s41375-023-01877-1
Leukemia, Vol. 37 Núm. 5 (may 2023) , p. 988-1005
|
|
|
2.
|
|
29 p, 5.2 MB |
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression
/
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortega-Sabater, C. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Thampi, Namitha (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández Fuentes, Narcís (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guerrero Murillo, Mercedes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez Moreno, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Campos, Diana (DiNA Science. S.A) ;
Giménez, Carles (DiNA Science. S.A) ;
Boer, Judith M. (Princess Maxima Center for Pediatric Oncology) ;
den Boer, Monique L. (Department of Pediatric Oncology and Hematology. Erasmus Medical Center - Sophia Children's Hospital) ;
Calvo, Gabriel F. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Camós, Mireia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Fuster, José Luis (Pediatric Hematology and Oncology Department. Hospital Clínico Universitario Virgen de la Arrixaca. Instituto Murciano de Investigación Biosanitaria (IMIB)) ;
Velasco, P. (Hospital Universitari Vall d'Hebron) ;
Ballerini, Paola (AP-HP. Service of Pediatric Hematology. Hopital Armand Trousseau) ;
Locatelli, Franco (Bambino Gesù Children's Hospital. Catholic University of Sacred Heart) ;
Mullighan, Charles G. (Department of Pathology. St. Jude Children's Research Hospital) ;
Spierings, Diana C.J. (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Foijer, Floris (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Pérez-García, Víctor M. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. [...]
2024 - 10.1038/s44321-023-00006-w
EMBO Molecular Medicine, Vol. 16 Núm. 1 (16 2024) , p. 64-92
|
|
|
3.
|
|
21 p, 3.1 MB |
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
/
Ramos-Muntada, Mireia (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blanco, Joan (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez-Cortez, Virginia Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
López-Millán, Belén (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Schwab, Claire (Newcastle University. Wolfson Childhood Cancer Research Centre) ;
Ortega, Margarita (Vall d'Hebron Institut d'Oncologia) ;
Velasco, Pablo (Hospital Universitari Vall d'Hebron) ;
Blanco, María L. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nomdedeu, Josep (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Ramírez, Manuel (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Minguela, Alfredo (Instituto Murciano de Investigación Biosanitaria) ;
Fuster, José Luis (Instituto Murciano de Investigación Biosanitaria) ;
Cuatrecasas, Esther (Institut de Recerca Sant Joan de Déu) ;
Camós, Mireia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Ballerini, Paola (Hôpital A. Trousseau) ;
Escherich, Gabriele (Department of Pediatric Hematology and Oncology. University Medical Center Hamburg) ;
Boer, Judith (Oncode Institute) ;
DenBoer, Monique (Erasmus MC - Sophia Children's Hospital) ;
Hernández-Rivas, Jesús M. (Instituto de Investigación Biomédica de Salamanca) ;
Calasanz, M.J (Universidad de Navarra) ;
Cazzaniga, Giovanni (Fondazione Tettamanti) ;
Harrison, Christine J. (Newcastle University. Wolfson Childhood Cancer Research Centre) ;
Menéndez Bujan, Pablo (Institució Catalana de Recerca i Estudis Avançats) ;
Molina, Oscar (Red Española de Terápias AvanzadasI)
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. [...]
2022 - 10.1002/1878-0261.13276
Molecular Oncology, Vol. 16 Núm. 16 (august 2022) , p. 2899-2919
|
|
|
4.
|
|
13 p, 4.7 MB |
Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis
/
Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rogers, R. B. (Department of Medicine. University of Cambridge. Cambridge Biomedical Campus) ;
Roy, A. (Department of Paediatrics. University of Oxford) ;
Schneider, P. (Princess Maxima Center for Pediatric Oncology) ;
Bardini, Michela (Università degli Studi di Milano-Bicocca) ;
Ballerini, Paola (Pediatric Hematology. A. Trousseau Hospital) ;
Cazzaniga, Giovanni (Centro Ricerca Tettamanti. Department of Pediatrics. University of Milano Bicocca. Fondazione MBBM) ;
Moreno, T. (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Revilla, C. (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Gut, Marta (Universitat Pompeu Fabra) ;
Valsecchi, M. G. (Interfant Trial Data Center. University of Milano-Bicocca) ;
Roberts, I. (MRC Molecular Haematology Unit. MRC Weatherall Institute of Molecular Medicine. University of Oxford) ;
Pieters, R. (Princess Maxima Center for Pediatric Oncology) ;
De Lorenzo, P. (Interfant Trial Data Center. University of Milano-Bicocca) ;
Varela, Ignacio (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Stam, R. W. (Princess Maxima Center for Pediatric Oncology) ;
Universitat Autònoma de Barcelona
Bcell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1 (MLL-AF4) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. [...]
2019 - 10.3324/haematol.2018.206375
Haematologica, Vol. 104 Núm. 6 (2019) , p. 1176-1188
|
|
|
5.
|
|
13 p, 3.4 MB |
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
/
López-Millán, Belén (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sanchéz-Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster, José Luis (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Ballerini, Paola (Pediatric Hematology. Armand Trousseau Hospital) ;
Suessbier, U. (University Hospital Zurich (Suïssa)) ;
Nombela-Arrieta, Cesar (University Hospital Zurich (Suïssa)) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. [...]
2019 - 10.1038/s41375-018-0353-0
Leukemia, Vol. 33 Núm. 7 (january 2019) , p. 1557-1569
|
|
|
6.
|
|
11 p, 5.7 MB |
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
/
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Baroni, Matteo Libero (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster, José Luis (Sección de Oncohematología Pediátrica. Hosp. Clin. Universitario Virgen de la Arrixaca and Instituto Murciano de Investigacion Biosanitaria) ;
Ballerini, Paola (Department of Pediatric Hemato-oncology. Armand-Trousseau Childrens Hospital) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Fuentes, Narcís (Universitat de Vic - Universitat Central de Catalunya) ;
Engel, P. (Universitat de Barcelona. Departament de Biomedicina) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. [...]
2020 - 10.1136/jitc-2020-000896
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (november 2020) , p. e000896
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
